Image Info

Figure 1.

Epigenetic and non-epigenetic alterations in the cellular aging predisposing LOAD. Epigenetic alterations including nucleosome remodeling, histone modifications, and DNA methylation leads to genomic instability, thereby causing accelerated cellular aging and crossing the threshold for LOAD predisposition in the healthy brain; non-epigenetic alterations including telomere shortening and immunosenescence influenced by epigenetic alterations and aging, in turn, leads to accelerated cellular aging in the brain and predispose LOAD symptoms

Declarations

Author contributions

KR and PG equally contributed to: Writing—original draft, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. In: Harris JR, editor. Protein aggregation and fibrillogenesis in cerebral and systemic amyloid disease. Dordrecht: Springer Netherlands; 2012. pp. 329–52. [DOI] [PubMed]

Ryan NS, Rossor MN. Correlating familial Alzheimer’s disease gene mutations with clinical phenotype. Biomark Med. 2010;4:99–112. [DOI] [PubMed] [PMC]

Alzheimer’s Association. 2019 Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2019;15:321–87. [DOI]

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. Erratum in: Lancet Neurol. 2014;13:757. [DOI] [PubMed]

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, et al.; Dominantly Inherited Alzheimer Network (DIAN). Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 2016;15:1317–25. Erratum in: Lancet Neurol. 2017;16:24. [DOI] [PubMed] [PMC]

Wattmo C, Wallin ÅK. Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimers Res Ther. 2017;9:70. [DOI] [PubMed] [PMC]

Reitz C, Rogaeva E, Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease: a distinction without a difference? Neurol Genet. 2020;6:e512. [DOI] [PubMed] [PMC]

Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, et al. Apolipoprotein E genotype and sex risk factors for alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74:1178–89. [DOI] [PubMed] [PMC]

Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18. Erratum in: Nat Rev Neurol. 2013;9:184. [DOI] [PubMed] [PMC]

10.

Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189. [DOI] [PubMed] [PMC]

11.

Fisher DW, Bennett DA, Dong H. Sexual dimorphism in predisposition to Alzheimer’s disease. Neurobiol Aging. 2018;70:308–24. [DOI] [PubMed] [PMC]

12.

Toricelli M, Pereira AAR, Souza Abrao G, Malerba HN, Maia J, Buck HS, et al. Mechanisms of neuroplasticity and brain degeneration: strategies for protection during the aging process. Neural Regen Res. 2021;16:58–67. [DOI] [PubMed] [PMC]

13.

Nakamura T, Naguro I, Ichijo H. Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases. Biochim Biophys Acta Gen Subj. 2019;1863:1398–409. [DOI] [PubMed]

14.

Raefsky SM, Mattson MP. Adaptive responses of neuronal mitochondria to bioenergetic challenges: roles in neuroplasticity and disease resistance. Free Radic Biol Med. 2017;102:203–16. [DOI] [PubMed] [PMC]

15.

Brunet A, Berger SL. Epigenetics of aging and aging-related disease. J Gerontol A Biol Sci Med Sci. 2014;69:S17–20. [DOI] [PubMed] [PMC]

16.

Pal S, Tyler JK. Epigenetics and aging. Sci Adv. 2016;2:e1600584. [DOI] [PubMed] [PMC]

17.

Xia Y, Dai R, Wang K, Jiao C, Zhang C, Xu Y, et al. Sex-differential DNA methylation and associated regulation networks in human brain implicated in the sex-biased risks of psychiatric disorders. Mol Psychiatry. 2021;26:835–48. [DOI] [PubMed] [PMC]

18.

Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464: 529–35. [DOI] [PubMed] [PMC]

19.

Liu RM. Aging, cellular senescence, and Alzheimer’s disease. Int J Mol Sci. 2022;23:1989. [DOI] [PubMed] [PMC]

20.

Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 2018;28:436–53. [DOI] [PubMed]

21.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153: 1194–217. [DOI] [PubMed] [PMC]

22.

Kubben N, Misteli T. Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases. Nat Rev Mol Cell Biol. 2017;18:595–609. [DOI] [PubMed] [PMC]

23.

Zhu Y, Liu X, Ding X, Wang F, Geng X. Telomere and its role in the aging pathways: telomere shortening, cell senescence and mitochondria dysfunction. Biogerontology. 2019;20:1–16. [DOI] [PubMed]

24.

Herrmann M, Pusceddu I, März W, Herrmann W. Telomere biology and age-related diseases. Clin Chem Lab Med. 2018;56:1210–22. [DOI] [PubMed]

25.

Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25: 585–621. [DOI] [PubMed]

26.

Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M. Unmasking transcriptional heterogeneity in senescent cells. Curr Biol. 2017;27:2652–60.E4. [DOI] [PubMed] [PMC]

27.

Kane AE, Sinclair DA. Epigenetic changes during aging and their reprogramming potential. Crit Rev Biochem Mol Biol. 2019;54:61–83. [DOI] [PubMed] [PMC]

28.

Basisty N, Meyer JG, Schilling B. Protein turnover in aging and longevity. Proteomics. 2018;18:e1700108. [DOI] [PubMed] [PMC]

29.

Uddin MS, Yu WS, Lim LW. Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer’s disease. Ageing Res Rev. 2021;70:101417. [DOI] [PubMed]

30.

Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018;217:51–63. [DOI] [PubMed] [PMC]

31.

Kaushik S, Cuervo AM. Proteostasis and aging. Nat Med. 2015;21:1406–15. [DOI] [PubMed]

32.

Li Z, Zhang Z, Ren Y, Wang Y, Fang J, Yue H, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology. 2021;22:165–87. [DOI] [PubMed] [PMC]

33.

Goodell MA, Rando TA. Stem cells and healthy aging. Science. 2015;350:1199–204. [DOI] [PubMed]

34.

Haran D. The free radical theory of aging: effect of age on serum copper levels. J Gerontol. 1965;20:151–3. [DOI] [PubMed]

35.

Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science. 2011;333:1109–12. [DOI] [PubMed] [PMC]

36.

Diamanti-Kandarakis E, Dattilo M, Macut D, Duntas L, Gonos ES, Goulis DG, et al.; COMBO ENDO TEAM: 2016. Mechanisms in endocrinology: aging and anti-aging: a combo-endocrinology overview. Eur J Endocrinol. 2017;176:R283–308. [DOI] [PubMed]

37.

Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY). 2012;4:166–75. [DOI] [PubMed] [PMC]

38.

Jack CR Jr, Shiung MM, Gunter JL, O’Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591–600. [DOI] [PubMed] [PMC]

39.

Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002;99:4703–7. [DOI] [PubMed] [PMC]

40.

Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci. 2006;7:30–40. [DOI] [PubMed]

41.

Ohm TG, Müller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience. 1995;64:209–17. [DOI] [PubMed]

42.

Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136–46. [DOI] [PubMed] [PMC]

43.

Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60:1495–500. [DOI] [PubMed]

44.

Hálová A, Janoutová J, Ewerlingová L, Janout V, Bonczek O, Zeman T, et al. CHAT gene polymorphism rs3810950 is associated with the risk of Alzheimer’s disease in the Czech population. J Biomed Sci. 2018;25:41. [DOI] [PubMed] [PMC]

45.

Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc. 1972;20:145–7. [DOI] [PubMed]

46.

Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs. 2002;11:1407–35. [DOI] [PubMed]

47.

Mielke MM, Lyketsos CG. Lipids and the pathogenesis of Alzheimer’s disease: is there a link? Int Rev Psychiatry. 2006;18:173–86. [DOI] [PubMed]

48.

Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease. J Neurochem. 2005;93:953–62. [DOI] [PubMed]

49.

Šerý O, Zeman T, Sheardová K, Vyhnálek M, Marková H, Laczó J, et al. Six genetically linked mutations in the CD36 gene significantly delay the onset of Alzheimer’s disease. Sci Rep. 2022;12:10994. [DOI] [PubMed] [PMC]

50.

Wang J, Yu JT, Tan MS, Jiang T, Tan L. Epigenetic mechanisms in Alzheimer’s disease: implications for pathogenesis and therapy. Ageing Res Rev. 2013;12:1024–41. [DOI] [PubMed]

51.

Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res Fundam Mol Mech Mutagen. 2006;600:46–57. [DOI] [PubMed]

52.

Bennett-Baker PE, Wilkowski J, Burke DT. Age-associated activation of epigenetically repressed genes in the mouse. Genetics. 2003;165:2055–62. [DOI] [PubMed] [PMC]

53.

Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS One. 2008;3:e2698. [DOI] [PubMed] [PMC]

54.

Irier HA, Jin P. Dynamics of DNA methylation in aging and Alzheimer’s disease. DNA Cell Biol. 2012;31:S42–8. [DOI] [PubMed] [PMC]

55.

Singal R, Ginder GD. DNA methylation. Blood. 1999;93:4059–70. [DOI] [PubMed]

56.

Laurent L, Wong E, Li G, Huynh T, Tsirigos A, Ong CT, et al. Dynamic changes in the human methylome during differentiation. Genome Res. 2010;20:320–31. [DOI] [PubMed] [PMC]

57.

Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 2004;32:4100–8. [DOI] [PubMed] [PMC]

58.

Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–5. [DOI] [PubMed] [PMC]

59.

Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929–30. [DOI] [PubMed] [PMC]

60.

Irvine RA, Lin IG, Hsieh CL. DNA methylation has a local effect on transcription and histone acetylation. Mol Cell Biol. 2002;22:6689–96. [DOI] [PubMed] [PMC]

61.

Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, Wiemels JL, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009;5:e1000602. [DOI] [PubMed] [PMC]

62.

Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49:359–67. [DOI] [PubMed] [PMC]

63.

Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:3156. Erratum in: Genome Biol. 2015;16:96. [DOI] [PubMed] [PMC]

64.

Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer’s disease related cognitive functioning. Aging (Albany NY). 2015;7:1198–211. [DOI] [PubMed] [PMC]

65.

Durso DF, Bacalini MG, Sala C, Pirazzini C, Marasco E, Bonafé M, et al. Acceleration of leukocytes’ epigenetic age as an early tumor and sex-specific marker of breast and colorectal cancer. Oncotarget. 2017;8:23237–45. [DOI] [PubMed] [PMC]

66.

Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of Parkinson’s disease patients. Aging (Albany NY). 2015;7:1130–42. [DOI] [PubMed] [PMC]

67.

Pan K, Chen Y, Roth M, Wang W, Wang S, Yee AS, et al. HBP1-mediated transcriptional regulation of DNA methyltransferase 1 and its impact on cell senescence. Mol Cell Biol. 2013;33:887–903. [DOI] [PubMed] [PMC]

68.

Lopatina N, Haskell JF, Andrews LG, Poole JC, Saldanha S, Tollefsbol T. Differential maintenance and de novo methylating activity by three DNA methyltransferases in aging and immortalized fibroblasts. J Cell Biochem. 2002;84:324–34. [DOI] [PubMed]

69.

Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic mechanisms in Alzheimer’s disease. Neurobiol Aging. 2011;32:1161–80. [DOI] [PubMed] [PMC]

70.

Humphries CE, Kohli MA, Nathanson L, Whitehead P, Beecham G, Martin E, et al. Integrated whole transcriptome and DNA methylation analysis identifies gene networks specific to late-onset Alzheimer’s disease. J Alzheimers Dis. 2015;44:977–87. [DOI] [PubMed]

71.

Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, et al. Altered CpG methylation in sporadic Alzheimer’s disease is associated with APP and MAPT dysregulation. Hum Mol Genet. 2014;23:648–56. [DOI] [PubMed]

72.

Coppieters N, Dieriks BV, Lill C, Faull RL, Curtis MA, Dragunow M. Global changes in DNA methylation and hydroxymethylation in Alzheimer’s disease human brain. Neurobiol Aging. 2014;35:1334–44. [DOI] [PubMed]

73.

Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, et al. Genome-wide DNA methylation differences between late-onset Alzheimer’s disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis. 2012;29:571–88. [DOI] [PubMed] [PMC]

74.

Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol. 2009;68:880–91. [DOI] [PubMed]

75.

Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Genda Y, Ukitsu M. Reduction with age in methylcytosine in the promoter region -224~-101 of the amyloid precursor protein gene in autopsy human cortex. Mol Brain Res. 1999;70:288–92. [DOI] [PubMed]

76.

West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer’s disease patient. J Mol Neurosci. 1995;6:141–6. [DOI] [PubMed]

77.

Piaceri I, Raspanti B, Tedde A, Bagnoli S, Sorbi S, Nacmias B. Epigenetic modifications in Alzheimer’s disease: cause or effect? J Alzheimers Dis. 2015;43:1169–73. [DOI] [PubMed]

78.

Guan JZ, Guan WP, Maeda T, Makino N. Analysis of telomere length and subtelomeric methylation of circulating leukocytes in women with Alzheimer’s disease. Aging Clin Exp Res. 2013;25:17–23. [DOI] [PubMed]

79.

Hernández HG, Sandoval-Hernández AG, Garrido-Gil P, Labandeira-Garcia JL, Zelaya MV, Bayon GF, et al. Alzheimer’s disease DNA methylome of pyramidal layers in frontal cortex: laser-assisted microdissection study. Epigenomics. 2018;10:1365–82. [DOI] [PubMed]

80.

Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. Nat Neurosci. 2014;17:1164–70. [DOI] [PubMed]

81.

Lardenoije R, van den Hove DLA, Havermans M, van Casteren A, Le KX, Palmour R, et al. Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer’s disease. Mol Cell Neurosci. 2018;86:1–15. [DOI] [PubMed] [PMC]

82.

Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009;78:273–304. [DOI] [PubMed]

83.

Yi SJ, Kim K. New insights into the role of histone changes in aging. Int J Mol Sci. 2020;21:8241. [DOI] [PubMed] [PMC]

84.

Hébert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32:199–206. [DOI] [PubMed]

85.

Somel M, Guo S, Fu N, Yan Z, Hu HY, Xu Y, et al. MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res. 2010;20:1207–18. [DOI] [PubMed] [PMC]

86.

Maes OC, An J, Sarojini H, Wang E. Murine microRNAs implicated in liver functions and aging process. Mech Ageing Dev. 2008;129:534–41. [DOI] [PubMed]

87.

Hackl M, Brunner S, Fortschegger K, Schreiner C, Micutkova L, Mück C, et al. miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging. Aging Cell. 2010;9:291–6. [DOI] [PubMed] [PMC]

88.

Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, Evans MK. microRNA expression patterns reveal differential expression of target genes with age. PLoS One. 2010;5:e10724. [DOI] [PubMed] [PMC]

89.

Vasa-Nicotera M, Chen H, Tucci P, Yang AL, Saintigny G, Menghini R, et al. miR-146a is modulated in human endothelial cell with aging. Atherosclerosis. 2011;217:326–30. [DOI] [PubMed]

90.

Herrera-Espejo S, Santos-Zorrozua B, Álvarez-González P, Lopez-Lopez E, Garcia-Orad Á. A systematic review of microRNA expression as biomarker of late-onset Alzheimer’s disease. Mol Neurobiol. 2019;56:8376–91. [DOI] [PubMed]

91.

Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729–40. [DOI] [PubMed]

92.

Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101:17312–5. [DOI] [PubMed] [PMC]

93.

Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens). 2009;8:7–22. [DOI] [PubMed]

94.

Scheller Madrid A, Rasmussen KL, Rode L, Frikke-Schmidt R, Nordestgaard BG, Bojesen SE. Observational and genetic studies of short telomeres and Alzheimer’s disease in 67,000 and 152,000 individuals: a Mendelian randomization study. Eur J Epidemiol. 2020;35:147–56. [DOI] [PubMed]

95.

Koh SH, Choi SH, Jeong JH, Jang JW, Park KW, Kim EJ, et al. Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer’s disease. Aging (Albany NY). 2020;12:4407–23. [DOI] [PubMed] [PMC]

96.

Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Perry G. Meta-analysis of telomere length in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci. 2016;71:1069–73. [DOI] [PubMed] [PMC]

97.

Guo Y, Yu H. Leukocyte telomere length shortening and Alzheimer’s disease etiology. J Alzheimers Dis. 2019;69:881–5. [DOI] [PubMed]

98.

Liu M, Huo YR, Wang J, Wang C, Liu S, Liu S, et al. Telomere shortening in Alzheimer’s disease patients. Ann Clin Lab Sci. 2016;46:260–5. [PubMed]

99.

Takata Y, Kikukawa M, Hanyu H, Koyama S, Shimizu S, Umahara T, et al. Association between ApoE phenotypes and telomere erosion in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci. 2012;67:330–5. [DOI] [PubMed]

100.

Ma F, Lv X, Du Y, Chen H, Liu S, Zhao J, et al. Association of leukocyte telomere length with mild cognitive impairment and Alzheimer’s disease: role of folate and homocysteine. Dement Geriatr Cogn Disord. 2019;48:56–67. [DOI] [PubMed]

101.

Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, et al. Telomere shortening in T cells correlates with Alzheimer’s disease status. Neurobiol Aging. 2003;24:77–84. [DOI] [PubMed]

102.

Scarabino D, Broggio E, Gambina G, Pelliccia F, Corbo RM. Common variants of human TERT and TERC genes and susceptibility to sporadic Alzheimers disease. Exp Gerontol. 2017;88:19–24. [DOI] [PubMed]

103.

Pawelec G. Immunity and ageing in man. Exp Gerontol. 2006;41:1239–42. [DOI] [PubMed]

104.

Macaulay R, Akbar AN, Henson SM. The role of the T cell in age-related inflammation. Age (Dordr). 2013;35:563–72. [DOI] [PubMed] [PMC]

105.

Fülöp T, Dupuis G, Witkowski JM, Larbi A. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016;68:84–91. [PubMed]

106.

Solana C, Tarazona R, Solana R. Immunosenescence of natural killer cells, inflammation, and Alzheimer’s disease. Int J Alzheimers Dis. 2018;2018:3128758. [DOI] [PubMed] [PMC]

107.

Regen F, Hellmann-Regen J, Costantini E, Reale M. Neuroinflammation and Alzheimer’s disease: implications for microglial activation. Curr Alzheimer Res. 2017;14:1140–48. [DOI] [PubMed]

108.

Cao W, Zheng H. Peripheral immune system in aging and Alzheimer’s disease. Mol Neurodegener. 2018;13:51. Erratum in: Mol Neurodegener. 2018;13:58. [DOI] [PubMed] [PMC]

109.

Le Page A, Bourgade K, Lamoureux J, Frost E, Pawelec G, Larbi A, et al. NK cells are activated in amnestic mild cognitive impairment but not in mild Alzheimer’s disease patients. J Alzheimers Dis. 2015;46:93–107. [DOI] [PubMed]

110.

Weng NP. Aging of the immune system: how much can the adaptive immune system adapt? Immunity. 2006;24:495–9. [DOI] [PubMed] [PMC]

111.

Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009;106:12145–50. [DOI] [PubMed] [PMC]

112.

Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and β-amyloid in the aging brain. J Neurosci. 2005;25:823–9. [DOI] [PubMed] [PMC]

113.

Román GC, Mancera-Páez O, Bernal C. Epigenetic factors in late-onset Alzheimer’s disease: MTHFR and CTH gene polymorphisms, metabolic transsulfuration and methylation pathways, and B vitamins. Int J Mol Sci. 2019;20:319. [DOI] [PubMed] [PMC]

114.

Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem. 1996;67:1328–31. [DOI] [PubMed]

115.

Hooshmand B, Solomon A, Kåreholt I, Leiviskä J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010;75:1408–14. [DOI] [PubMed]

116.

Payão SL, Smith MD, Bertolucci PH. Differential chromosome sensitivity to 5-azacytidine in Alzheimer’s disease. Gerontology. 1998;44:267–71. [DOI] [PubMed]